These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 39114974)

  • 21. Dietary ellagic acid therapy for CNS autoimmunity: Targeting on Alloprevotella rava and propionate metabolism.
    Han B; Shi L; Bao MY; Yu FL; Zhang Y; Lu XY; Wang Y; Li DX; Lin JC; Jia W; Li X; Zhang Y
    Microbiome; 2024 Jun; 12(1):114. PubMed ID: 38915127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome".
    Pröbstel AK; Baranzini SE
    Neurotherapeutics; 2018 Jan; 15(1):126-134. PubMed ID: 29147991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.
    Calvo-Barreiro L; Eixarch H; Montalban X; Espejo C
    Autoimmun Rev; 2018 Feb; 17(2):165-174. PubMed ID: 29191793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-chain fatty acids and gut microbiota in multiple sclerosis.
    Melbye P; Olsson A; Hansen TH; Søndergaard HB; Bang Oturai A
    Acta Neurol Scand; 2019 Mar; 139(3):208-219. PubMed ID: 30427062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The gut microbiome and microbial translocation in multiple sclerosis.
    Mirza A; Mao-Draayer Y
    Clin Immunol; 2017 Oct; 183():213-224. PubMed ID: 28286112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of gut microbiota in multiple sclerosis-review of a new pathophysiological hypothesis and potential treatment target.
    Olejnik P; Buczma K; Cudnoch-Jędrzejewska A; Kasarełło K
    Immunol Res; 2024 Aug; 72(4):554-565. PubMed ID: 38446328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the gut to treat multiple sclerosis.
    Ghezzi L; Cantoni C; Pinget GV; Zhou Y; Piccio L
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal Dysbiosis and Tryptophan Metabolism in Autoimmunity.
    Brown J; Robusto B; Morel L
    Front Immunol; 2020; 11():1741. PubMed ID: 32849620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiome and multiple sclerosis: New insights and perspective.
    Esmaeil Amini M; Shomali N; Bakhshi A; Rezaei S; Hemmatzadeh M; Hosseinzadeh R; Eslami S; Babaie F; Aslani S; Torkamandi S; Mohammadi H
    Int Immunopharmacol; 2020 Nov; 88():107024. PubMed ID: 33182024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The gut microbiota perspective for interventions in MS.
    Zoledziewska M
    Autoimmun Rev; 2019 Aug; 18(8):814-824. PubMed ID: 31176875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases.
    Kim D; Zeng MY; Núñez G
    Exp Mol Med; 2017 May; 49(5):e339. PubMed ID: 28546562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
    Sun MF; Shen YQ
    Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Gut-derived Short-Chain Fatty Acids in Multiple Sclerosis.
    Saadh MJ; Ahmed HM; Alani ZK; Al Zuhairi RAH; Almarhoon ZM; Ahmad H; Ubaid M; Alwan NH
    Neuromolecular Med; 2024 Apr; 26(1):14. PubMed ID: 38630350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The gut microbiome molecular mimicry piece in the multiple sclerosis puzzle.
    Elsayed NS; Aston P; Bayanagari VR; Shukla SK
    Front Immunol; 2022; 13():972160. PubMed ID: 36045671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?
    Adamczyk-Sowa M; Medrek A; Madej P; Michlicka W; Dobrakowski P
    J Immunol Res; 2017; 2017():7904821. PubMed ID: 28316999
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of type 1 diabetes on the composition and functional potential of gut microbiome in children and adolescents: possible mechanisms, current knowledge, and challenges.
    Mokhtari P; Metos J; Anandh Babu PV
    Gut Microbes; 2021; 13(1):1-18. PubMed ID: 34101547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis.
    Kujawa D; Laczmanski L; Budrewicz S; Pokryszko-Dragan A; Podbielska M
    Gut Microbes; 2023 Dec; 15(2):2274126. PubMed ID: 37979154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The second brain: The connection between gut microbiota composition and multiple sclerosis.
    Farshbafnadi M; Agah E; Rezaei N
    J Neuroimmunol; 2021 Nov; 360():577700. PubMed ID: 34482269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pomegranate peel extract ameliorates the severity of experimental autoimmune encephalomyelitis via modulation of gut microbiota.
    Lu XY; Han B; Deng X; Deng SY; Zhang YY; Shen PX; Hui T; Chen RH; Li X; Zhang Y
    Gut Microbes; 2020 Nov; 12(1):1857515. PubMed ID: 33382357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?
    Parodi B; Kerlero de Rosbo N
    Front Immunol; 2021; 12():718220. PubMed ID: 34621267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.